Mesoporous silica formulation strategies for drug dissolution enhancement: A review

Expert Opinion on Drug Delivery

Volumn 13, Issue 1, 2016, Pages 93-108

  Mccarthy, Carol A ^a   Ahern, Robert J ^a   Dontireddy, Rakesh ^a   Ryan, Katie B ^a   Crean, Abina M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

dissolution; loading method; mesoporous silica; poorly water soluble drugs; solid dispersion

Indexed keywords

DRUG CARRIER; SILICON DIOXIDE; WATER;

BIOAVAILABILITY; CHEMISTRY; DRUG RELEASE; HUMAN; MEDICINAL CHEMISTRY; PARTICLE SIZE; POROSITY; PROCEDURES; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG LIBERATION; HUMANS; PARTICLE SIZE; POROSITY; SILICON DIOXIDE; SOLUBILITY; WATER;

EID: 84955212393     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1100165     Document Type: Article

References (126)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000; 44 (1): 235-249
2. van Hoogevest P, Liu X, Fahr A. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. Expert Opin Drug Deliv. 2011; 8 (11): 1481-1500
3. Monkhouse DC, Lach JL. Use of adsorbents in enhancement of drug dissolution. I. J Pharm Sci. 1972; 61 (9): 1430-1435
4. Unger K, Rupprecht H, Valentin B., et al. The use of porous and surface modified silicas as drug delivery and stabilizing agents. Drug Dev Ind Pharm. 1983; 9 (1-2): 69-91
5. Vallet-Regi M, Ramila A, Del Real R., et al. A new property of MCM-41: drug delivery system. Chem Mater. 2001; 13 (2): 308-311
6. Van Speybroeck M, Barillaro V, Thi TD., et al. Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. J Pharm Sci. 2009; 98 (8): 2648-2658
7. Mellaerts R, Aerts CA, Humbeeck JV., et al. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem Commun. 2007; 13: 1375-1377
8. Heikkilä T, Salonen J, Tuura J., et al. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm. 2007; 331 (1): 133-138
9. Kresge C, Leonowicz M, Roth W., et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992; 359 (6397): 710-712
10. Salonen J, Kaukonen AM, Hirvonen J., et al. Mesoporous silicon in drug delivery applications. J Pharm Sci. 2008; 97 (2): 632-653
11. Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm. 2010; 390 (2): 165-173
12. U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products; 2015 [ cited 2015 Sep 14 ]. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/getiigWEB.cfm
13. Fu C, Liu T, Li L., et al. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013; 34 (10): 2565-2575
14. Hudson SP, Padera RF, Langer R., et al. The biocompatibility of mesoporous silicates. Biomaterials. 2008; 29 (30): 4045-4055
15. Manzano M, Colilla M, Vallet-Regí M. Drug delivery from ordered mesoporous matrices. Expert Opin Drug Deliv. 2009; 6 (12): 1383-1400
16. Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano-And micro-particles. Adv Drug Deliv Rev. 2012; 64 (15): 1800-1819
17. Rowe RC, Sheskey PJ, Owen SC., et al. Handbook of pharmaceutical excipients. Vol. 6. London: Pharmaceutical press; 2006
18. Kim J. Synthesis of MCM-48 single crystals. Chem Commun. 1998; 2: 259-260
19. Izquierdo-Barba I, Martinez Á, Doadrio AL., et al. Release evaluation of drugs from ordered three-dimensional silica structures. Eur J Pharm Sci. 2005; 26 (5): 365-373
20. Zhao D, Feng J, Huo Q., et al. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998; 279 (5350): 548-552
21. Inagaki S, Koiwai A, Suzuki N., et al. Syntheses of highly ordered mesoporous materials, FSM-16, derived from Kanemite. Bull Chem Soc Jpn. 1996; 69 (5): 1449-1457
22. Jansen J, Shan Z, Marchese L., et al. A new templating method for three-dimensional mesopore networks. Chem Commun. 2001; 8: 713-714
23. Takeuchi H, Nagira S, Yamamoto H., et al. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm. 2005; 293 (1-2): 155-164
24. Kinnari P, Mäkilä E, Heikkilä T., et al. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm. 2011; 414 (1-2): 148-156
25. Friedrich H, Fussnegger B, Kolter K., et al. Dissolution rate improvement of poorly water-soluble drugs obtained by adsorbing solutions of drugs in hydrophilic solvents onto high surface area carriers. Eur J Pharm Biopharm. 2006; 62 (2): 171-177
26. Bend Research. Spray-Dried NanoAdsorbate (SDNA) Technology; 2014 [ cited 2015 Feb 4 ]. Available from: http://www.bendresearch.com/drug-delivery-Technologies/spray-dried-composite-sdc-Technology
27. Tang F, Li L, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012; 24 (12): 1504-1534
28. Azaïs T, Tourné-Péteilh C, Aussenac F., et al. Solid-state NMR study of ibuprofen confined in MCM-41 material. Chem Mater. 2006; 18 (26): 6382-6390
29. Shen SC, Ng WK, Chia L., et al. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties. J Pharm Sci. 2010; 99 (4): 1997-2007
30. Charnay C, Bégu S, Tourné-Péteilh C., et al. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biophar. 2004; 57 (3): 533-540
31. Hong S, Shen S, Tan DCT., et al. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods. Drug Deliv. 2015;July 21: 1-12
32. Sliwinska-Bartkowiak M, Dudziak G, Gras R., et al. Freezing behavior in porous glasses and MCM-41. Colloids Surf A Physicochem Eng Asp. 2001; 187: 523-529
33. Brás AR, Fonseca IM, Dionísio M., et al. Influence of nanoscale confinement on the molecular mobility of ibuprofen. J Phys Chem C. 2014; 118 (25): 13857-13868
34. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000; 17 (4): 397-404
35. FUJI SILYSIA CHEMICAL LTD. Sylysia; 2015 [ cited 2015 Sep 14 ]. Available from: http://www.fujisilysia.com/products/sylysia/
36. Grace WR, Conn C. Syloid silica excipients for pharmaceutical applications; 2014 [ cited 2015 Apr 28 ]. Available from: https://grace.com/pharma-And-biotech/en-us/Documents/Syloid/B561b-SYLOID-8.5x11VERSION-9-18-14-FINAL.pdf
37. Gumaste SG, Pawlak SA, Dalrymple DM., et al. Development of solid SEDDS, IV: effect of adsorbed lipid and surfactant on tableting properties and surface structures of different silicates. Pharm Res. 2013; 30 (12): 3170-3185
38. Galarneau A, Nader M, Guenneau F., et al. Understanding the stability in water of mesoporous SBA-15 and MCM-41. J Phys Chem C. 2007; 111 (23): 8268-8277
39. Merck Millipore. Merck Millipore Introduces Parteck® SLC, Silica-based Excipient for Enhanced Drug Solubility and Bioavailability. Darmstadt: Merck Millipore Corporation; 2013
40. Andersson J, Rosenholm J, Areva S., et al. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro-And mesoporous silica matrices. Chem Mater. 2004; 16 (21): 4160-4167
41. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv. 2011; 8 (10): 1361-1378
42. Prestidge CA, Barnes TJ, Lau C-H., et al. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin Drug Deliv. 2007; 4 (2):101-110
43. Ahern RJ, Hanrahan JP, Tobin JM., et al. Comparison of fenofibrate-mesoporous silica drug-loading processes for enhanced drug delivery. Eur J Pharm Sci. 2013; 50 (3-4): 400-409
44. Mellaerts R, Jammaer JAG, Van Speybroeck M., et al. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen. Langmuir. 2008; 24 (16): 8651-8659
45. Waters LJ, Bedford S, Parkes GMB. Controlled microwave processing applied to the pharmaceutical formulation of ibuprofen. AAPS PharmSciTech. 2011; 12 (4): 1038-1043
46. Waters LJ, Hussain T, Parkes G., et al. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation. Eur J Pharm Biopharm. 2013; 85 (3): 936-941
47. Qu F, Zhu G, Lin H., et al. A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials. J Solid State Chem. 2006; 179 (7): 2027-2035
48. Ambrogi V, Perioli L, Pagano C., et al. MCM-41 for furosemide dissolution improvement. Microporous Mesoporous Mater. 2012; 147 (1): 343-349
49. Qian KK, Bogner RH. Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems. J Pharm Sci. 2012; 101 (2): 444-463
50. ICH. Impurities: guideline for residual solvents Q3C(R5) [Internet]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2011 Feb. [cited 2014 Oct 20]. Available from: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q3C/Step4/Q3C-R5-Step4.pdf
51. Hata H, Saeki S, Kimura T., et al. Adsorption of taxol into ordered mesoporous silicas with various pore diameters. Chem Mater. 1999; 11 (4): 1110-1119
52. Heikkilä T, Salonen J, Tuura J., et al. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv. 2007; 14 (6): 337-347
53. Lehto V, Riikonen J, Santos H. Drug loading and characterization of porous silicon materials. In: Santos HA, editor. Porous silicon for biomedical applications. Cambridge: Woodhead Publishing Limited; 2014. p. 337
54. Mellaerts R, Houthoofd K, Elen K., et al. Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. Microporous Mesoporous Mater. 2010; 130 (1): 154-161
55. Van Speybroeck M, Mols R, Mellaerts R., et al. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur J Pharm Biopharm. 2010; 75 (3): 354-365
56. Van Speybroeck M, Mellaerts R, Thi TD., et al. Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs. J Pharm Sci. 2011; 100 (11): 4864-4876
57. Kruk M, Jaroniec M, Ko CH., et al. Characterization of the porous structure of SBA-15. Chem Mater. 2000; 12 (7): 1961-1968
58. Vetere A. A short-cut method to predict the solubilities of solids in supercritical carbon dioxide. Fluid Phase Equilib. 1998; 148 (1-2): 83-93
59. Gignone A, Manna L, Ronchetti S., et al. Incorporation of clotrimazole in ordered mesoporous silica by supercritical CO 2. Microporous Mesoporous Mater. 2014; 200: 291-296
60. Ahern RJ, Crean AM, Ryan KB. The influence of supercritical carbon dioxide (SC-CO 2) processing conditions on drug loading and physicochemical properties. Int J Pharm. 2012; 439 (1): 92-99
61. Limnell T, Santos HA, Mäkilä E., et al. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. J Pharm Sci. 2011; 100 (8): 3294-3306
62. Bahl D, Hudak J, Bogner RH. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm Dev Technol. 2008; 13 (3): 255-269
63. Aerts CA, Verraedt E, Mellaerts R., et al. Tunability of pore diameter and particle size of amorphous microporous silica for diffusive controlled release of drug compounds. J Phys Chem C. 2007; 111 (36): 13404-13409
64. Horcajada P, Ramila A, Perez-Pariente J., et al. Influence of pore size of MCM-41 matrices on drug delivery rate. Microporous Mesoporous Mater. 2004; 68 (1): 105-109
65. Tozuka Y, Wongmekiat A, Kimura K., et al. Effect of pore size of FSM-16 on the entrapment of flurbiprofen in mesoporous structures. Chem Pharm Bull. 2005; 53 (8): 974-977
66. Ukmar T, Maver U, Planinšek O., et al. Understanding controlled drug release from mesoporous silicates: theory and experiment. J Control Release. 2011; 155 (3): 409-417
67. Gao L, Sun J, Zhang L., et al. Influence of different structured channels of mesoporous silicate on the controlled ibuprofen delivery. Mater Chem Phys. 2012; 135 (2-3): 786-797
68. Zhu Y-F, Shi J-L, Li Y-S., et al. Hollow mesoporous spheres with cubic pore network as a potential carrier for drug storage and its in vitro release kinetics. J Mater Res. 2005; 20 (1): 54-61
69. Zhang Y, Zhi Z, Jiang T., et al. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release. 2010; 145 (3): 257-263
70. Rengarajan G, Enke D, Steinhart M., et al. Stabilization of the amorphous state of pharmaceuticals in nanopores. J Mater Chem. 2008; 18 (22): 2537-2539
71. Jia LJ, Shen JY, Li ZY., et al. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs. Int J Pharm. 2012; 439 (1-2): 81-91
72. Shen S-C, Ng WK, Chia L., et al. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. Int J Pharm. 2011; 410 (1-2): 188-195
73. Hu Y, Wang J, Zhi Z., et al. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J Colloid Interface Sci. 2011; 363 (1): 410-417
74. Xu W, Riikonen J, Lehto V-P. Mesoporous systems for poorly soluble drugs. Int J Pharm. 2013; 453 (1): 181-197
75. Miura H, Kanebako M, Shirai H., et al. Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state 13C NMR spectroscopy. Int J Pharm. 2011; 410 (1-2): 61-67
76. Van Speybroeck M, Mellaerts R, Mols R., et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010; 41 (5): 623-630
77. Qi L, Ma J, Cheng H., et al. Micrometer-sized mesoporous silica spheres grown under static conditions. Chem Mater. 1998; 10 (6): 1623-1626
78. Slowing II, Vivero-Escoto JL, Wu C-W., et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60 (11): 1278-1288
79. Qu F, Zhu G, Huang S., et al. Controlled release of captopril by regulating the pore size and morphology of ordered mesoporous silica. Microporous Mesoporous Mater. 2006; 92 (1-3): 1-9
80. Manzano M, Aina V, Areán CO., et al. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization. Chem Eng J. 2008; 137 (1): 30-37
81. Hu J, Rogers TL, Brown J., et al. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. Pharm Res. 2002; 19 (9): 1278-1284
82. Kumar D, Sailaja Chirravuri SV, Shastri NR. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac. Int J Pharm. 2014; 461 (1-2): 459-468
83. Song SW, Hidajat K, Kawi S. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions. Langmuir. 2005; 21 (21): 9568-9575
84. Balas F, Manzano M, Horcajada P., et al. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006; 128 (25): 8116-8117
85. Doadrio JC, Sousa EM, Izquierdo-Barba I., et al. Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern. J Mater Chem. 2006; 16 (5): 462-466
86. Qu F, Zhu G, Huang S., et al. Effective controlled release of captopril by silylation of mesoporous MCM-41. Chem Phys Chem. 2006; 7 (2): 400-406
87. Tang Q, Yao X, Dong W., et al. Studies on a new carrier of trimethylsilyl-modified mesoporous material for controlled drug delivery. J Control Release. 2006; 114 (1): 41-46
88. Moritz M, Łaniecki M. SBA-15 mesoporous material modified with APTES as the carrier for 2-(3-benzoylphenyl) propionic acid. Appl Surf Sci. 2012; 258 (19): 7523-7529
89. Guo Z, Liu X-M, Ma L., et al. Effects of particle morphology, pore size and surface coating of mesoporous silica on naproxen dissolution rate enhancement. Colloids Surf B Biointerfaces. 2013; 101: 228-235
90. Nastase S, Bajenaru L, Matei C., et al. Ordered mesoporous silica and aluminosilicate-Type matrix for amikacin delivery systems. Microporous Mesoporous Mater. 2013; 182: 32-39
91. Carmona D, Balas F, Santamaria J. Pore ordering and surface properties of FDU-12 and SBA-15 mesoporous materials and their relation to drug loading and release in aqueous environments. Mater Res Bull. 2014; 59: 311-322
92. Jambhrunkar S, Qu Z, Popat A., et al. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica nanoparticles. J Colloid Interface Sci. 2014; 434: 218-225
93. Yoncheva K, Popova M, Szegedi A., et al. Functionalized mesoporous silica nanoparticles for oral delivery of budesonide. J Solid State Chem. 2014; 211: 154-161
94. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997; 86 (1): 1-12
95. Morris KR, Griesser UJ, Eckhardt CJ., et al. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev. 2001; 48 (1): 91-114
96. Limnell T, Riikonen J, Salonen J., et al. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. Int J Pharm. 2007; 343 (1-2): 141-147
97. Limnell T, Heikkilä T, Santos HA., et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm. 2011; 416 (1): 242-251
98. Qian K, Wurster D, Bogner R. Spontaneous crystalline-To-Amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 3: effect of moisture. Pharm Res. 2012; 29 (10): 2698-2709
99. Hailu SA, Bogner RH. Complex effects of drug/silicate ratio, solid-state equivalent pH, and moisture on chemical stability of amorphous quinapril hydrochloride coground with silicates. J Pharm Sci. 2011; 100 (4): 1503-1515
100. Pan X, Julian T, Augsburger L. Increasing the dissolution rate of a low-solubility drug through a crystalline-Amorphous transition: a case study with indomethicin. Drug Dev Ind Pharm. 2008; 34 (2): 221-231
101. Bahl D, Bogner R. Amorphization of indomethacin by co-grinding with Neusilin US2: amorphization kinetics, physical stability and mechanism. Pharm Res. 2006; 23 (10): 2317-2325
102. Mellaerts R, Roeffaers MBJ, Houthoofd K., et al. Molecular organization of hydrophobic molecules and co-Adsorbed water in SBA-15 ordered mesoporous silica material. Phys Chem Chem Phys. 2011; 13 (7): 2706-2713
103. Shalaev EY, Zografi G. How does residual water affect the solid-state degradation of drugs in the amorphous state? J Pharm Sci. 1996; 85 (11): 1137-1141
104. Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001; 48 (1): 115-136
105. Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013; 453 (1): 12-24
106. Vialpando M, Martens JA, Van den Mooter G. Potential of ordered mesoporous silica for oral delivery of poorly soluble drugs. Ther Deliv. 2011; 2 (8): 1079-1091
107. Wang S. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mater. 2009; 117 (1): 1-9
108. Xue JM, Shi M. PLGA/mesoporous silica hybrid structure for controlled drug release. J Control Release. 2004; 98 (2): 209-217
109. Bui TX, Choi H. Adsorptive removal of selected pharmaceuticals by mesoporous silica SBA-15. J Hazard Mater. 2009; 168 (2): 602-608
110. Turku I, Sainio T, Paatero E. Thermodynamics of tetracycline adsorption on silica. Environ Chem Lett. 2007; 5 (4): 225-228
111. Ahern RJ. Application of mesoporous silica for the oral delivery of poorly water soluble drugs, in school of pharmacy. Ireland: University College Cork; 2013
112. Atkin R, Craig VSJ, Wanless EJ., et al. Mechanism of cationic surfactant adsorption at the solid-Aqueous interface. Adv Colloid Interface Sci. 2003; 103 (3): 219-304
113. Guzman HR, Tawa M, Zhang Z., et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007; 96 (10): 2686-2702
114. Vandecruys R, Peeters J, Verreck G., et al. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007; 342 (1): 168-175
115. Mellaerts R, Mols R, Kayaert P., et al. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. Int J Pharm. 2008; 357 (1-2): 169-179
116. Mellaerts R, Mols R, Jammaer JAG., et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm. 2008; 69 (1): 223-230
117. Vialpando M, Aerts A, Persoons J., et al. Evaluation of ordered mesoporous silica as a carrier for poorly soluble drugs: influence of pressure on the structure and drug release. J Pharm Sci. 2011; 100 (8): 3411-3420
118. Kiekens F, Eelen S, Verheyden L., et al. Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. J Pharm Sci. 2012; 101 (3): 1136-1144
119. Peng T, Zhu C, Huang Y., et al. Improvement of the stability of doxycycline hydrochloride pellet-containing tablets through a novel granulation technique and proper excipients. Powder Technol. 2015; 270,. (Part A): 221-229
120. Vialpando M, Backhuijs F, Martens JA., et al. Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen. Eur J Pharm Biopharm. 2012; 81 (1): 190-198
121. Cassiers K, Linssen T, Mathieu M., et al. A detailed study of thermal, hydrothermal, and mechanical stabilities of a wide range of surfactant assembled mesoporous silicas. Chem Mater. 2002; 14 (5): 2317-2324
122. Choudhari Y, Reddy U, Monsuur F., et al. Comparative evaluation of porous silica based carriers for lipids and liquid drug formulations. Mesoporous Biomater. 2014; 1: 1
123. Wang ZH, Chen B, Quan GL., et al. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica. Int J Nanomedicine. 2012; 7: 5807-5818
124. Formac Pharmaceuticals. Formac pharmaceuticals; pipeline; 2015 [ cited 2015 Mar 25 ]. Available from: http://www.formacpharma.com/index.php?page=pipeline&sub=6
125. Glantreo Ltd. Glantreo; innovative nanomaterials for drug delivery; 2015 [ cited 2015 Mar 25 ]. Available from: http://www.glantreo.com/application-Areas/pharmaceuticals/
126. Nanologica AB. NLAB silica-next generation platform technology in drug delivery; 2014 [ cited 2015 Apr 29 ]; Available from: http://www.nanologica.com/drug-delivery